Trial Number

016-20

Age range

18 years and older

Gender

Male or Female

Enrolling Patients

Yes

Patients undergoing treatment with durvalumab for unresectable Stage III non-small cell lung cancer (NSCLC) after 2 or more cycles of concurrent platinum-based chemotherapy and radiation therapy can experience pulmonary adverse events (AEs) that lead to treatment discontinuation and morbidity. This study, ON TRAX, is a pilot study to evaluate the potential benefit of multiparametric mobile applications and connected medical devices in collecting data to facilitate or improve early identification of pulmonary AEs in patients with unresectable Stage III NSCLC receiving durvalumab treatment. The outcomes of this study will determine whether this multiparametric mobile technology will be progressed to a fully powered study for the early detection of pneumonitis and pulmonary AEs in patients with unresectable Stage III NSCLC. This project seeks to understand if the multiparametric mobile technology devices integrate well into a patient’s daily life with minimal burden and to collect vital signs and respiratory data. These devices can then track and detect changes in a patient’s vital signs and respiratory function and aid physicians in detection of pulmonary AEs.

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.